Addiction

Adial Pharmaceuticals Encouraged By U.S. Senate Support for Expanded Clinical Trial Endpoints Beyond Abstinence in Alcohol and Substance Use Disorder Treatments

U.S. Senate Appropriations Report Further Validates Adial’s Therapeutic Approach and Promotes a More Contemporary Patient Focused Regulatory EnvironmentGLEN ALLEN, Va.,...

MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage

error: Content is protected !!